2894-18-0 Usage
Uses
Used in Pharmaceutical Industry:
3,4,5-Trimethoxy-acetoacetanilide is used as a key intermediate in the synthesis of various medications, primarily for its anesthetic properties. It plays a crucial role in the production of local anesthetics and analgesics, such as lidocaine and prilocaine, which are widely used in medical procedures to numb tissues and alleviate pain.
Additionally, due to its potential applications in the field of organic synthesis and medicinal chemistry, 3,4,5-trimethoxy-acetoacetanilide may be utilized in the development of new pharmaceutical compounds, expanding its use beyond its current applications in anesthetics and analgesics. Its versatility in chemical reactions and its ability to contribute to the medicinal properties of synthesized compounds make it a valuable component in the ongoing research and development of novel therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 2894-18-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,8,9 and 4 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 2894-18:
(6*2)+(5*8)+(4*9)+(3*4)+(2*1)+(1*8)=110
110 % 10 = 0
So 2894-18-0 is a valid CAS Registry Number.
InChI:InChI=1/C13H17NO5/c1-8(15)5-12(16)14-9-6-10(17-2)13(19-4)11(7-9)18-3/h6-7H,5H2,1-4H3,(H,14,16)
2894-18-0Relevant academic research and scientific papers
Quinolinehydrazones as inhibitors of retroviral reverse transcriptase
Bartolucci,Cellai,Di Filippo,Brizzi,Pellerano,Savini,Benedetto,Elia
, p. 945 - 952 (2007/10/02)
The inhibitory activity of a series of 2- and 4-quinolinehydrazones on retroviral reverse transcriptase has been studied on enzymes from M-MuLV, RAV-2, and on a crude lysate of HIV-1, assuming the first two enzymes as potential models of the third. The highest activity is mainly found in lipophilic, water soluble 4-quinolinehydrazones. The inhibitory activity of these compounds decreases in changing from the M-MuLV to the RAV-2, and HIV-1 enzymes, in this order.
